183 related articles for article (PubMed ID: 8737953)
1. Recent status of the antisense oligonucleotide approaches in oncology.
Ma L; Calvo F
Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
[TBL] [Abstract][Full Text] [Related]
2. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
Chen HX
Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
[No Abstract] [Full Text] [Related]
4. Antisense therapy.
Narayanan R; Akhtar S
Curr Opin Oncol; 1996 Nov; 8(6):509-15. PubMed ID: 8971471
[TBL] [Abstract][Full Text] [Related]
5. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
6. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical experience of antisense therapy for solid tumors.
Webb MS; Zon G
Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
11. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058
[No Abstract] [Full Text] [Related]
12. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide technology in the development of cancer therapeutics.
Tseng BY; Brown KD
Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
[No Abstract] [Full Text] [Related]
14. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
Warzocha K; Wotowiec D
Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
[TBL] [Abstract][Full Text] [Related]
15. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
17. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
19. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of microRNAs in cancer.
Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
